Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant Journal Article
| Authors: | Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Jakubowski, A. A.; Gyurkocza, B.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Cai, S. F.; Daniyan, A.; Famulare, C.; Cuello, B. M.; Podoltsev, N. A.; Roshal, M.; Giralt, S.; Perales, M. A.; Seropian, S.; Cho, C.; Zeidan, A. M.; Prebet, T.; Stein, E. M.; Tallman, M. S.; Goldberg, A. D.; Stahl, M. |
| Article Title: | Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant |
| Abstract: | The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option. © 2021 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | transplant; aml; mds; acute myeloid leukemia; venetoclax |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 62 |
| Issue: | 14 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2021-01-01 |
| Start Page: | 3394 |
| End Page: | 3401 |
| Language: | English |
| DOI: | 10.1080/10428194.2021.1966788 |
| PUBMED: | 34477024 |
| PROVIDER: | scopus |
| PMCID: | PMC9012492 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work